Co-Inventors
Leppla, Stephen
Neumann, Sebastian
Heumann, Rolf
Palaga, Dennis
Merritt, Carly
Therapeutic Areas
Rare/Neglected Diseases
Infectious Disease
Immunology
Research Products
Research Equipment
Plasmids/Vectors
Antibodies
The technology offers a novel and efficient method for inducing targeted DNA recombination using a tripartite fusion protein, LFn-NLS-Cre, in combination with anthrax toxin protective antigen (PA). This system enables precise genetic manipulation in cells carrying a gene flanked by loxP sites, allowing for specific recombination events. Unlike other inducible systems that require multiple injections, our technology requires only a single administration, reducing experimental complexity and stress on animals. Recombination can occur rapidly, with effects seen in as little as 10 hours post-injection. The simplicity, efficiency, and specificity of our method make it a valuable tool for researchers in a wide range of genetic and molecular biology studies.
Commercial Applications
The technology has broad potential applications across various fields, including basic research, biotechnology, and gene therapy. In basic research, it can be used to study gene function and regulation by allowing researchers to control the expression of specific genes in a targeted manner. In biotechnology, the method could facilitate the development of genetically modified organisms (GMOs) and the production of recombinant proteins. Moreover, the technology holds promise for gene therapy applications, where precise genetic manipulation is crucial. By enabling targeted DNA recombination, this method could potentially be used to correct genetic mutations or introduce therapeutic genes into specific cell types. Its versatility and precision make it applicable to a wide range of research and therapeutic areas.
Competitive Advantages
This technology offers several key competitive advantages over existing methods for inducing DNA recombination. First, unlike traditional methods that require multiple injections or complex breeding schemes, our system requires only a single administration, saving time and resources. Second, our method allows for rapid recombination, with effects observed in as little as 10 hours, compared to other systems that may take days to achieve similar results. Third, our technology is highly specific, targeting only cells carrying loxP sites, thereby minimizing off-target effects and improving the accuracy of genetic manipulation. Additionally, our system is cost-effective and does not require the use of viral vectors or complex cell culture techniques, making it accessible to a wide range of researchers. Overall, these advantages position our technology as a powerful and efficient tool for targeted genetic manipulation.
